Shanghai Pharmaceuticals Holding Co., Ltd

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, MCK has a market cap of 88.60B. Regarding current trading prices, SHPMY is priced at $7.17, while MCK trades at $706.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas MCK's P/E ratio is 32.39. In terms of profitability, SHPMY's ROE is +0.06%, compared to MCK's ROE of -1.15%. Regarding short-term risk, SHPMY is more volatile compared to MCK. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, COR has a market cap of 56.61B. Regarding current trading prices, SHPMY is priced at $7.17, while COR trades at $291.95.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas COR's P/E ratio is 41.47. In terms of profitability, SHPMY's ROE is +0.06%, compared to COR's ROE of +1.85%. Regarding short-term risk, SHPMY is more volatile compared to COR. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, CAH has a market cap of 36.72B. Regarding current trading prices, SHPMY is priced at $7.17, while CAH trades at $152.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas CAH's P/E ratio is 23.82. In terms of profitability, SHPMY's ROE is +0.06%, compared to CAH's ROE of -0.50%. Regarding short-term risk, SHPMY is more volatile compared to CAH. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ABC has a market cap of 36.15B. Regarding current trading prices, SHPMY is priced at $7.17, while ABC trades at $179.98.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ABC's P/E ratio is 21.92. In terms of profitability, SHPMY's ROE is +0.06%, compared to ABC's ROE of +1.72%. Regarding short-term risk, SHPMY is more volatile compared to ABC. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, HSIC has a market cap of 8.16B. Regarding current trading prices, SHPMY is priced at $7.17, while HSIC trades at $66.58.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas HSIC's P/E ratio is 21.83. In terms of profitability, SHPMY's ROE is +0.06%, compared to HSIC's ROE of +0.11%. Regarding short-term risk, SHPMY is less volatile compared to HSIC. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, SHPMF has a market cap of 8.13B. Regarding current trading prices, SHPMY is priced at $7.17, while SHPMF trades at $1.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas SHPMF's P/E ratio is 10.47. In terms of profitability, SHPMY's ROE is +0.06%, compared to SHPMF's ROE of +0.06%. Regarding short-term risk, SHPMY is more volatile compared to SHPMF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, SHTDY has a market cap of 8.04B. Regarding current trading prices, SHPMY is priced at $7.17, while SHTDY trades at $12.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas SHTDY's P/E ratio is 6.72. In terms of profitability, SHPMY's ROE is +0.06%, compared to SHTDY's ROE of +0.09%. Regarding short-term risk, SHPMY is more volatile compared to SHTDY. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, SHTDF has a market cap of 7.64B. Regarding current trading prices, SHPMY is priced at $7.17, while SHTDF trades at $2.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas SHTDF's P/E ratio is 6.45. In terms of profitability, SHPMY's ROE is +0.06%, compared to SHTDF's ROE of +0.06%. Regarding short-term risk, SHPMY is more volatile compared to SHTDF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, CAKFY has a market cap of 5.37B. Regarding current trading prices, SHPMY is priced at $7.17, while CAKFY trades at $4.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas CAKFY's P/E ratio is -68.33. In terms of profitability, SHPMY's ROE is +0.06%, compared to CAKFY's ROE of -0.02%. Regarding short-term risk, SHPMY is more volatile compared to CAKFY. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, AMFPF has a market cap of 4.28B. Regarding current trading prices, SHPMY is priced at $7.17, while AMFPF trades at $19.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas AMFPF's P/E ratio is 26.03. In terms of profitability, SHPMY's ROE is +0.06%, compared to AMFPF's ROE of +0.13%. Regarding short-term risk, SHPMY is more volatile compared to AMFPF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, PBH has a market cap of 4.11B. Regarding current trading prices, SHPMY is priced at $7.17, while PBH trades at $82.93.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas PBH's P/E ratio is 19.47. In terms of profitability, SHPMY's ROE is +0.06%, compared to PBH's ROE of +0.12%. Regarding short-term risk, SHPMY is more volatile compared to PBH. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, GALNF has a market cap of 3.75B. Regarding current trading prices, SHPMY is priced at $7.17, while GALNF trades at $75.25.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas GALNF's P/E ratio is 20.23. In terms of profitability, SHPMY's ROE is +0.06%, compared to GALNF's ROE of +0.12%. Regarding short-term risk, SHPMY is more volatile compared to GALNF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, MAHLY has a market cap of 3.40B. Regarding current trading prices, SHPMY is priced at $7.17, while MAHLY trades at $16.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas MAHLY's P/E ratio is 9.91. In terms of profitability, SHPMY's ROE is +0.06%, compared to MAHLY's ROE of +0.06%. Regarding short-term risk, SHPMY is more volatile compared to MAHLY. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, MEPDF has a market cap of 3.08B. Regarding current trading prices, SHPMY is priced at $7.17, while MEPDF trades at $14.80.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas MEPDF's P/E ratio is 8.97. In terms of profitability, SHPMY's ROE is +0.06%, compared to MEPDF's ROE of +0.08%. Regarding short-term risk, SHPMY is less volatile compared to MEPDF. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, PDCO has a market cap of 2.77B. Regarding current trading prices, SHPMY is priced at $7.17, while PDCO trades at $31.33.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas PDCO's P/E ratio is 20.48. In terms of profitability, SHPMY's ROE is +0.06%, compared to PDCO's ROE of +0.14%. Regarding short-term risk, SHPMY is more volatile compared to PDCO. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ALFRY has a market cap of 2.44B. Regarding current trading prices, SHPMY is priced at $7.17, while ALFRY trades at $13.42.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ALFRY's P/E ratio is 12.90. In terms of profitability, SHPMY's ROE is +0.06%, compared to ALFRY's ROE of +0.05%. Regarding short-term risk, SHPMY is more volatile compared to ALFRY. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ARHCF has a market cap of 2.27B. Regarding current trading prices, SHPMY is priced at $7.17, while ARHCF trades at $11.87.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ARHCF's P/E ratio is 9.97. In terms of profitability, SHPMY's ROE is +0.06%, compared to ARHCF's ROE of +0.05%. Regarding short-term risk, SHPMY is more volatile compared to ARHCF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, SZUKF has a market cap of 1.72B. Regarding current trading prices, SHPMY is priced at $7.17, while SZUKF trades at $30.30.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas SZUKF's P/E ratio is 11.43. In terms of profitability, SHPMY's ROE is +0.06%, compared to SZUKF's ROE of +0.04%. Regarding short-term risk, SHPMY is more volatile compared to SZUKF. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, IUSDF has a market cap of 1.66B. Regarding current trading prices, SHPMY is priced at $7.17, while IUSDF trades at $23.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas IUSDF's P/E ratio is 30.05. In terms of profitability, SHPMY's ROE is +0.06%, compared to IUSDF's ROE of +0.12%. Regarding short-term risk, SHPMY is less volatile compared to IUSDF. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, GRDN has a market cap of 1.60B. Regarding current trading prices, SHPMY is priced at $7.17, while GRDN trades at $25.35.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas GRDN's P/E ratio is -14.16. In terms of profitability, SHPMY's ROE is +0.06%, compared to GRDN's ROE of -1.16%. Regarding short-term risk, SHPMY is more volatile compared to GRDN. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, MEDOF has a market cap of 1.28B. Regarding current trading prices, SHPMY is priced at $7.17, while MEDOF trades at $50.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas MEDOF's P/E ratio is 73.53. In terms of profitability, SHPMY's ROE is +0.06%, compared to MEDOF's ROE of +0.03%. Regarding short-term risk, SHPMY is less volatile compared to MEDOF. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ARRJF has a market cap of 836.17M. Regarding current trading prices, SHPMY is priced at $7.17, while ARRJF trades at $3.07.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ARRJF's P/E ratio is 18.06. In terms of profitability, SHPMY's ROE is +0.06%, compared to ARRJF's ROE of +0.06%. Regarding short-term risk, SHPMY is less volatile compared to ARRJF. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, OMI has a market cap of 628.85M. Regarding current trading prices, SHPMY is priced at $7.17, while OMI trades at $8.14.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas OMI's P/E ratio is -1.72. In terms of profitability, SHPMY's ROE is +0.06%, compared to OMI's ROE of -0.45%. Regarding short-term risk, SHPMY is less volatile compared to OMI. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, WGRX has a market cap of 237.39M. Regarding current trading prices, SHPMY is priced at $7.17, while WGRX trades at $4.57.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas WGRX's P/E ratio is -30.47. In terms of profitability, SHPMY's ROE is +0.06%, compared to WGRX's ROE of -1.74%. Regarding short-term risk, SHPMY is less volatile compared to WGRX. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ZYXI has a market cap of 63.65M. Regarding current trading prices, SHPMY is priced at $7.17, while ZYXI trades at $2.11.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ZYXI's P/E ratio is 23.39. In terms of profitability, SHPMY's ROE is +0.06%, compared to ZYXI's ROE of -0.24%. Regarding short-term risk, SHPMY is less volatile compared to ZYXI. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, GEG has a market cap of 53.85M. Regarding current trading prices, SHPMY is priced at $7.17, while GEG trades at $1.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas GEG's P/E ratio is -190.00. In terms of profitability, SHPMY's ROE is +0.06%, compared to GEG's ROE of +0.00%. Regarding short-term risk, SHPMY is more volatile compared to GEG. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, HX has a market cap of 53.37M. Regarding current trading prices, SHPMY is priced at $7.17, while HX trades at $2.24.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas HX's P/E ratio is -1.84. In terms of profitability, SHPMY's ROE is +0.06%, compared to HX's ROE of -0.04%. Regarding short-term risk, SHPMY is less volatile compared to HX. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, EXHI has a market cap of 15.06M. Regarding current trading prices, SHPMY is priced at $7.17, while EXHI trades at $0.34.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas EXHI's P/E ratio is N/A. In terms of profitability, SHPMY's ROE is +0.06%, compared to EXHI's ROE of +0.00%. Regarding short-term risk, SHPMY is more volatile compared to EXHI. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, NSVGF has a market cap of 8.48M. Regarding current trading prices, SHPMY is priced at $7.17, while NSVGF trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas NSVGF's P/E ratio is -1.00. In terms of profitability, SHPMY's ROE is +0.06%, compared to NSVGF's ROE of +0.21%. Regarding short-term risk, SHPMY is less volatile compared to NSVGF. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ENMI has a market cap of 7.66M. Regarding current trading prices, SHPMY is priced at $7.17, while ENMI trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ENMI's P/E ratio is -0.20. In terms of profitability, SHPMY's ROE is +0.06%, compared to ENMI's ROE of +0.51%. Regarding short-term risk, SHPMY is less volatile compared to ENMI. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, RDGT has a market cap of 6.44M. Regarding current trading prices, SHPMY is priced at $7.17, while RDGT trades at $1.10.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas RDGT's P/E ratio is -0.33. In terms of profitability, SHPMY's ROE is +0.06%, compared to RDGT's ROE of N/A. Regarding short-term risk, SHPMY is less volatile compared to RDGT. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, PDRX has a market cap of 4.26M. Regarding current trading prices, SHPMY is priced at $7.17, while PDRX trades at $2.76.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas PDRX's P/E ratio is 2.56. In terms of profitability, SHPMY's ROE is +0.06%, compared to PDRX's ROE of -0.07%. Regarding short-term risk, SHPMY is more volatile compared to PDRX. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, KOSK has a market cap of 3.98M. Regarding current trading prices, SHPMY is priced at $7.17, while KOSK trades at $0.01.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas KOSK's P/E ratio is -0.18. In terms of profitability, SHPMY's ROE is +0.06%, compared to KOSK's ROE of -0.13%. Regarding short-term risk, SHPMY is more volatile compared to KOSK. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, ITNS has a market cap of 533194.00. Regarding current trading prices, SHPMY is priced at $7.17, while ITNS trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas ITNS's P/E ratio is -0.03. In terms of profitability, SHPMY's ROE is +0.06%, compared to ITNS's ROE of +0.01%. Regarding short-term risk, SHPMY is less volatile compared to ITNS. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, PHRX has a market cap of 5171.00. Regarding current trading prices, SHPMY is priced at $7.17, while PHRX trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas PHRX's P/E ratio is N/A. In terms of profitability, SHPMY's ROE is +0.06%, compared to PHRX's ROE of +0.85%. Regarding short-term risk, SHPMY is less volatile compared to PHRX. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, CHME has a market cap of 2380.00. Regarding current trading prices, SHPMY is priced at $7.17, while CHME trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas CHME's P/E ratio is N/A. In terms of profitability, SHPMY's ROE is +0.06%, compared to CHME's ROE of +0.04%. Regarding short-term risk, SHPMY is more volatile compared to CHME. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, MLTO has a market cap of 1700.00. Regarding current trading prices, SHPMY is priced at $7.17, while MLTO trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas MLTO's P/E ratio is -0.00. In terms of profitability, SHPMY's ROE is +0.06%, compared to MLTO's ROE of N/A. Regarding short-term risk, SHPMY is less volatile compared to MLTO. This indicates potentially lower risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, TGVN has a market cap of 120.00. Regarding current trading prices, SHPMY is priced at $7.17, while TGVN trades at $0.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas TGVN's P/E ratio is -0.00. In terms of profitability, SHPMY's ROE is +0.06%, compared to TGVN's ROE of N/A. Regarding short-term risk, SHPMY is more volatile compared to TGVN. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.

SHPMY plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SHPMY stands at 8.49B. In comparison, CVET comparison data is unavailable. Regarding current trading prices, SHPMY is priced at $7.17, while CVET trades at $20.99.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SHPMY currently has a P/E ratio of 9.69, whereas CVET's P/E ratio is -69.97. In terms of profitability, SHPMY's ROE is +0.06%, compared to CVET's ROE of -0.06%. Regarding short-term risk, SHPMY is more volatile compared to CVET. This indicates potentially higher risk in terms of short-term price fluctuations for SHPMY.